PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Switching from alteplase to tenecteplase as the thrombolytic used routinely for acute ischemic stroke is having multiple benefits for one US hospital system. Tenecteplase was developed as a more ...

Compared with the standard clot-busting medication alteplase, the newer clot-buster known as tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) stroke in mobile ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Giving the clot-busting medication alteplase at the site of a blocked brain artery after blood clot removal may increase the number of patients who fully recover, according to preliminary ...

LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...

CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- ...

ST. LOUIS – A new drug therapy has been administered at SSM Health hospitals since June 2021 that is proving to dissolve blood clots, particularly larger clots, in a shorter amount of time. Normally, ...

Even after a blood clot is removed from a large artery in the brain via a minimally invasive procedure to treat a clot-caused stroke, delivering the clot-busting medication alteplase to the area may ...